Torrent Pharmaceuticals Limited
TORNTPHARM
株式のランク
#1203
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
株価
$50.16
時価総額
$19.08B
変化（1日）
-0.30%
変化（1年）
22.94%
国
IN
取引 Torrent Pharmaceuticals Limited (TORNTPHARM)
カテゴリー
Healthcare
Torrent Pharmaceuticals Limited（TORNTPHARM）の収益
Jun 2026 時点の収益 TTM: $1.72B
Torrent Pharmaceuticals Limited の最新の財務報告によると、現在の収益 (TTM) は $1.72B です。2024 年には $1.29B の収益があり、これは 2023 年の $1.17B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Torrent Pharmaceuticals Limited の収益履歴（2005 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.72B | 27.98% |
| 2025 | $1.35B | 4.66% |
| 2024 | $1.29B | 9.91% |
| 2023 | $1.17B | 4.44% |
| 2022 | $1.12B | 2.50% |
| 2021 | $1.09B | 3.76% |
| 2020 | $1.05B | -4.62% |
| 2019 | $1.10B | 20.92% |
| 2018 | $913.81M | 1.90% |
| 2017 | $896.80M | -10.88% |
| 2016 | $1.01B | 34.94% |
| 2015 | $745.76M | -3.94% |
| 2014 | $776.35M | 31.37% |
| 2013 | $590.99M | 15.51% |
| 2012 | $511.64M | 7.45% |
| 2011 | $476.15M | 11.61% |
| 2010 | $426.62M | 32.82% |
| 2009 | $321.20M | -5.13% |
| 2008 | $338.57M | 13.00% |
| 2007 | $299.62M | 37.98% |
| 2006 | $217.15M | 73.11% |
| 2005 | $125.44M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 283.67% |
IN
|
